TNFAIP6 and brain infarction: Accordingly, systemic acute administration of recombinant mouse TSG-6 elevated brain levels of the M2 marker Ym1 and provided significant neuroprotection by reducing brain infarct volume and general neurological deficits in mice subjected to transient MCAo.